10-QPeriod: Q2 FY2004

CARDINAL HEALTH INC Quarterly Report for Q2 Ended Dec 31, 2003

Filed February 17, 2004For Securities:CAH

Summary

Cardinal Health, Inc. (CAH) reported strong revenue growth for the second quarter of fiscal year 2004, with operating revenue increasing by 11% year-over-year to $14.1 billion. This growth was driven by increased sales volume across all segments, particularly in Pharmaceutical Distribution and Provider Services, and Medical Products and Services. Despite revenue growth, operating earnings saw a slight decline of 1% year-over-year due to the impact of special items and ongoing business model transitions within the Pharmaceutical Distribution segment, which is moving towards a "just-in-time", fee-for-service model. However, earnings from continuing operations and net earnings showed a positive trend, increasing by 4% and 2% respectively. The company also completed two strategic acquisitions during the quarter, Intercare and Medicap, further expanding its service offerings and global reach. Overall, the company maintains a positive outlook, driven by diversified segment performance and strategic initiatives.

Key Highlights

  • 1Strong revenue growth of 11% to $14.1 billion, driven by increased sales volume across all segments.
  • 2Operating earnings experienced a slight 1% decline year-over-year, primarily due to the impact of special items and business model transition in the Pharmaceutical Distribution segment.
  • 3Net earnings and earnings from continuing operations showed positive growth of 2% and 4% respectively, indicating underlying profitability.
  • 4Completion of two strategic acquisitions: Intercare (European pharmaceutical products and services) and Medicap (franchisor of pharmacies), strengthening the company's market position and service offerings.
  • 5Significant share repurchase program: Company repurchased approximately 17.0 million shares for $1.0 billion, impacting cash and equity.
  • 6The Pharmaceutical Distribution and Provider Services segment is undergoing a transition to a 'just-in-time', fee-for-service model, impacting vendor margins and necessitating a shift in revenue recognition for certain sales.
  • 7Positive outlook for the Pharmaceutical Distribution business due to the Medicare Prescription Drug, Improvement, and Modernization Act, which may increase volume demand and generic drug utilization.

Frequently Asked Questions

Cardinal Health experienced strong revenue growth driven by a higher sales volume across all its segments, revenue growth from existing and new customers, and the addition of new corporate agreements with healthcare providers that integrate the company's diverse offerings. Acquisitions also contributed to revenue.

The slight decline in operating earnings was primarily influenced by the impact of 'special items' and an ongoing business model transition within the Pharmaceutical Distribution and Provider Services segment. This segment is shifting from an inventory accumulation model to a 'just-in-time', fee-for-service model, which has led to temporary mismatches in vendor margins.

The acquisitions of Intercare (a European pharmaceutical products and services company) and Medicap (a franchisor of pharmacies) are strategically important as they expand Cardinal Health's global reach, enhance its proprietary sterile manufacturing capabilities, and broaden its participation in key growing markets. These acquisitions align with the company's strategy to expand its role as a provider of services to the healthcare industry.

The company repurchased approximately 17.0 million common shares for $1.0 billion. This significant repurchase reduced the company's cash and equivalents and shareholders' equity, reflecting a strategic decision to return capital to shareholders.